Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KNIGHTS: Niraparib/Abiraterone Acetate in High-Risk Oligometastatic Prostate Cancer
NCT06212583Phase 2Active, not recruiting
- Sponsor
- University of Maryland, Baltimore
- Start
- Apr 2024
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of niraparib and abiraterone in prostate cancer (PCa) (2 arms), sponsored by University of Maryland, Baltimore. Primary endpoint: Prostate Specific Antigen evaluation at 18 months. Started Apr 2024; status: active, not recruiting.
02
Drugs
niraparibabiraterone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06212583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06212583.